Our recent article has been described by Dr. Robert Lowery in an article entitled Lung Cancer Cells Use NF-κB Pathway to Subvert Third Generation EGFR Kinase Inhibitors, as follows: “One of these, gefitinib, was the second kinase inhibitor to be approved by the FDA, in 2003, for the treatment of non-small-cell lung cancer (NSCLC); a second EGFR inhibitor, erlotinib, was approved the following year. (The Bcr-Abl inhibitor, imatinib (Gleevec), was approved for breast cancer in 2001.) Activating EGFR mutations were discovered in a subgroup of NSCLC patients from the initial gefitinib clinical trials. These mutations, which render the tyrosine kinase constitutively active in the absence of ligand, occur in about 50% of lung adenocarcinomas from Asian patients and about 10% for non-Asians. Though discovery of the activating mutations initiated a new paradigm of personalized therapy for NSCLC and vastly improved patient response rates, most patients eventually relapse. In the majority of cases acquired resistance is caused by the T790M secondary mutation, which renders EGFR insensitive to gefitinib and other first line inhibitors. For the last several years, researchers have been intensively focused on how to overcome acquired resistance to first generation EGFR inhibitors.
The complete article can be read at: www.bellbrooklabs.com
Our description of the paper is at: www.cancerpharmacology.org/nf-κb-drives-acquired-resistance